[8-K] CervoMed Inc. Reports Material Event

Rhea-AI Filing Summary

CervoMed Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025. The press release is attached to the Form 8-K as Exhibit 99.1 and is incorporated by reference into Item 2.02, and the filing states that the information is being furnished under Item 2.02 rather than filed for purposes of Section 18 of the Exchange Act. Item 9.01 lists Exhibits 99.1 (the press release) and 104 (cover page interactive data file).

Insights

Financial Analyst

TL;DR: Routine furnishing of Q2 results via press release; the 8-K includes no financial figures, so the filing itself is neutral for valuation.

The Form 8-K indicates the company issued a press release with quarterly results for the period ended June 30, 2025, and attached it as Exhibit 99.1. Because the item is explicitly furnished and the 8-K does not present financial line items or metrics, this filing does not by itself change the financial picture investors can analyze. Market participants must review Exhibit 99.1 for concrete revenue, earnings, cash flow, or reserve details before updating valuations.

Corporate Governance / IR Specialist

TL;DR: The company adhered to disclosure norms by furnishing results and providing an Inline XBRL cover page; classification as furnished limits Section 18 liability.

CervoMed followed a common disclosure path by furnishing a press release under Item 2.02 and including Exhibits 99.1 and 104. The filing’s explicit statement that the information is furnished, not filed, is a standard legal distinction that reduces the risk of Section 18 liability for the disclosed content. This indicates routine investor-relations practice, but does not substitute for reviewing the press release itself for material financial and operational detail.

false 0001053691 0001053691 2025-08-11 2025-08-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

August 11, 2025

Date of Report (Date of earliest event reported)

CervoMed Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-37942		30-0645032
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)
20 Park Plaza, Suite 424 Boston, Massachusetts				02116
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (617) 744-4400

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		CRVO		NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02         Results of Operations and Financial Condition

On August 11, 2025, CervoMed Inc. issued a press release announcing financial results as of and for the quarter ended June 30, 2025. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information included in or incorporated by reference into this Item 2.02 (including Exhibit 99.1) is being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act.

Item 9.01                  Financial Statements and Exhibits

(d)         Exhibits

Exhibit No.	Description
99.1	Press Release, issued August 11, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 11, 2025	CervoMed Inc.
	By:	/s/ William Elder
	Name:	William Elder
	Title:	Chief Financial Officer, General Counsel & Secretary

3

FAQ

When did CervoMed (CRVO) announce quarterly results?

The company issued a press release announcing financial results for the quarter ended June 30, 2025, which is attached to the Form 8-K as Exhibit 99.1.

Does the 8-K include the full financial statements for Q2 2025?

No. The Form 8-K furnishes a press release as Exhibit 99.1 but does not include formatted financial statements or line-item financial data within the filing text.

Is the information in the 8-K considered "filed" with the SEC?

The filing explicitly states the information is being furnished under Item 2.02 and is not deemed to be "filed" for purposes of Section 18 of the Exchange Act.

What exhibits are listed in the Form 8-K for CervoMed?

Item 9.01 lists Exhibit 99.1 (Press Release) and Exhibit 104 (Cover Page Interactive Data File).

Where should investors look for the detailed financial numbers?

Investors should review the attached press release, Exhibit 99.1, which the 8-K incorporates by reference for detailed financial results.